Summary During the interval 1968-74, 17,032 women aged 25-39 years were recruited to the Oxford-Family Planning Association contraceptive study, more than half of whom were using oral contraceptives. These women have been followed up 
A large number of case-control studies of the relationship between oral contraceptives and breast cancer have been published (see McPherson et al., 1987; Vessey, 1987) . Considered together, these studies provide strong evidence that the use of oral contraceptives in the middle of the fertile years (say, between the ages of 25 and 39 years) has no adverse effect on breast cancer risk. There remains, however, considerable anxiety about the effects of oral contraceptive use at an early age, especially before first term pregnancy; thus some studies have yielded reassuring findings about such exposure (Vessey et al., 1982; Stadel et al., 1985; Paul et al., 1986 ) while others have not (Pike et al., 1983; Meirik et al., 1986; McPherson et al., 1987) .
Not surprisingly, few data are available from cohort studies about oral contraceptive use and breast cancer. We last reported on this topic from the Oxford-Family Planning Association (Oxford-FPA) cohort study in 1981 when 72 incident cases of breast cancer had occurred (Vessey et al., 1981) . We now present our latest findings, based on 189 incident cancers.
Methods
A detailed description of the methods used in the Oxford-FPA study has been given elsewhere (Vessey et al., 1976) . In brief, 17,032 women were recruited at 17 large family planning clinics in England and Scotland during 1968-74 . At the time of recruitment, each of these women had to be (i) aged 25-39 years, (ii) married, (iii) a white British subject, (iv) willing to participate and (v) either a current user of oral contraceptives with at least 5 months' use or a current user of a diaphragm or an intrauterine device with at least 5 months' use without previous exposure to the pill. During follow-up, each women is questioned at return visits to the clinic by a doctor or nurse and certain items of information are recorded on a special form, including details of pregnancies and their outcome, changes in contraceptive practices and reasons for referral to hospital. Women who stop attending the clinic are sent a postal version of the questionnaire and, if this is not returned, are interviewed on the telephone or at a home visit. Each hospital admission is followed up by writing to the consultant concerned and a copy of the relevant discharge summary is obtained (with histological details if appropriate). The work in each clinic is co-ordinated by a part-time research assistant and follow-up has been maintained with an annual loss rate because of withdrawal of co-operation or loss of contact of only about 0.3%. The records of all the participants are 'labelled' in the National Health Service Central Registries in Southport and Edinburgh, leading to automatic notification of deaths and of a substantial proportion of cancer registrations (see Villard-Mackintosh et al., 1988) .
When women reach the age of 45 years, they are divided into three groups: (i) those who have never used the pill; (ii) those with 8 or more years use of the pill; and (iii) the remainder. Only the women in the first two of these groups are subsequently followed up intensively in the way described above. The women in the third group (of whom there were 2,879 on 1 September 1987) are followed up only by means of the National Health Service Central Registries. For these reasons, data for women aged 45 years or more are shown separately in the analyses which follow; women in the third group are excluded because the ascertainment of breast cancer among them is known to be incomplete (Villard-Mackintosh et al., 1988) . The results presented here thus concern 189 women with histologically proven cancer of the breast first diagnosed during follow-up before 1 September 1987.
The first part of the analysis (the cohort analysis) is based on the computation of woman-years of observation in the contraceptive groups compared; incidence rates are standardised by the indirect method as described by Vessey et al. (1976) . The influence of a wide range of potentially confounding variables was investigated including age, parity, age at first term pregnancy, age at natural or artificial menopause, type of artificial menopause (hysterectomy with retention of one or more ovaries, removal of both ovaries with or without hysterectomy), social class, weight, height, Quetelets index and history of hospital referral for benign breast disease. Social class and measures of body size showed no important relationship with breast cancer risk in this study. Of the other variables, age had by far the most important confounding effect, but we also took the influence of parity and age at first term pregnancy into account in the analyses concerning women aged up to 44 years, and these variables plus age at menopause and type of menopause into account in the analyses concerning the older women. The inclusion of a history of hospital referral for benign breast disease in the adjustment procedure had only a trivial effect on the results. In view of the uncertainty as to whether or not it is appropriate to adjust for this variable in analyses pertaining to oral contraceptive use (see Stadel & Schlesselman, 1986) , we decided to omit it in the tables presented here.
The second part of the analysis, which is concerned with pill brand and with a search for a latent effect following oral contraceptive use before first term pregnancy, utilises casecontrol methodology. We The relationship between breast cancer risk and interval since oral contraceptives were first used is examined in Table  II . As before, age was the only important confounding variable. In the younger age group (and in 5 year subgroups within it), there was no suggestion of any association. Among women aged 45 years or more, the rates were significantly heterogeneous, mainly because of a deficiency of cancers in the longest interval group. We have been unable to find any explanation for this observation, and the matter will be kept under review as more data accumulate. The data in Tables I-III are reassuring, but on the basis of published work (both our own and that of others) we expected them to be so. Adjusted for age (2 year groups), parity (0, 1-2, >3 births), age at first term pregnancy (no pregnancy, < 19, 20-24, >25 years) and, for those aged >45, age and type of menopause (still menstruating; natural menopause at age <40, 40-44, >45; hysterectomy with at least one ovary retained at age <40, 40-44, >45; bilateral oophorectomy with or without hysterectomy at age <40, 40-44, >45). Age at first term pregnancy was unknown in two clinics, so age at marriage plus one year was substituted. Ages 25-44 years, X =0.69 (n.s.). Ages >45 years, X'=4.11 (n.s.). 
Discussion
The findings in studies of oral contraceptive use and breast cancer have recently been reviewed in detail elsewhere (McPherson et al., 1987; Vessey, 1987) and the interested reader is referred to these reviews. In brief, as we stated earlier, there is a consensus that the use of oral contraceptives by women in the middle of the fertile years (say between 25 and 39 years) has no adverse effect on breast cancer risk and our findings add weight to this conclusion. There is, on the other hand, continuing anxiety about the effects of oral contraceptive use at an early age, especially before first term pregnancy. Furthermore, McPherson et al. (1987) suggested that any adverse effect might particularly be associated with oral contraceptives containing ethinyloestradiol (rather than mestranol) and might be enhanced with the passage of time from exposure. Schlesselman et al. (1987 Schlesselman et al. ( , 1988 
